
USPH Stock Forecast & Price Target
USPH Analyst Ratings
Bulls say
US Physical Therapy Inc is poised for continued growth, particularly in its industrial injury prevention business, which has demonstrated strong momentum, contributing to an anticipated revenue increase of 17.1% year-over-year in this segment. The company has raised its adjusted EBITDA guidance for FY/25 to a range of $93 million to $97 million, reflecting an 8.6% increase compared to the previous year. Overall, these developments underscore a positive outlook for the firm as it capitalizes on its key revenue sources and operational efficiencies.
Bears say
US Physical Therapy Inc. may face challenges in the coming years as it will encounter its first year in 2026 without pricing pressure from its Medicare business since prior to the COVID pandemic. The company's reliance on multiple payment sources, including managed care programs and Medicare/Medicaid, raises concerns about consistent revenue generation, particularly amidst potential regulatory changes. Lastly, the company generates the majority of its revenue from its Physical therapy operations segment, which could limit growth opportunities in the context of evolving market dynamics and competitive pressures.
This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.
USPH Analyst Forecast & Price Prediction
Start investing in USPH
Order type
Buy in
Order amount
Est. shares
0 shares